ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company’s primary product candidate, Gencaro (bucindolol hydrochloride), is a pharmacologically beta-blocker and mild vasodilator that it is evaluating in a clinical trial for the treatment of atrial fibrillation, in patients with heart failure and left ventricular systolic dysfunction. The company is testing hypothesis in a Phase 2B/3 clinical trial of Gencaro, known as GENETIC-AF. Strategy The key elements of the company’s strategy are to advance the development of Gencaro; build a cardiovascular pipeline; and leverage its existing assets. Research and Development For the year ended December 31, 2014, the company’s research and development expenses totaled $5.6 million.
arca biopharma inc
(ABIO:Consolidated Issue listed on NASDAQ Capital Market)
11080 CirclePoint Road
Westminster, CO 80020
|No competitor information is available for ABIO.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact ARCA BIOPHARMA INC, please visit www.arcabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.